Altimmune (FRA:3G0) E10: €-19.76 (As of Mar. 2026)


FRA:3G0 Altimmune Inc FRA:3G0
30 GF Score
Price €2.52
! 2 Warning Signs
View Full Analysis

What is Altimmune E10?

Altimmune FRA:3G0 +3.93% 30 E10 is €-19.76 as of Mar. 2026. GuruFocus rates FRA:3G0 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Altimmune's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.156. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-19.76 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 14.30% per year. During the past 5 years, the average E10 Growth Rate was 10.90% per year. During the past 10 years, the average E10 Growth Rate was 29.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Altimmune was 53.00% per year. The lowest was 7.90% per year. And the median was 25.80% per year.

As of today (2026-07-01), Altimmune's current stock price is €2.515. Altimmune's E10 for the quarter that ended in Mar. 2026 was €-19.76. Altimmune's Shiller PE Ratio of today is .


Altimmune  (FRA:3G0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Altimmune E10 Related Terms


Altimmune E10 Historical Data

* Premium members only.

The historical data trend for Altimmune's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altimmune E10 Chart

Altimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.23 -35.29 -30.64 -26.94 -20.66

Altimmune Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.50 -22.29 -21.69 -20.66 -19.76

FRA:3G0 vs RGNX, TRAX, ASMB: E10 Comparison

For the Biotechnology subindustry, Altimmune's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altimmune Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Altimmune's Shiller PE Ratio falls into.


FRA:3G0
30GF Score
Altimmune Inc FRA:3G0
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altimmune E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Altimmune's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.156/330.2130*330.2130
=-0.156

Current CPI (Mar. 2026) = 330.2130.

Altimmune Quarterly Data

per share eps CPI Adj_EPS
201606 -6.675 241.018 -9.145
201609 -18.978 241.428 -25.957
201612 -13.083 241.432 -17.894
201703 -19.074 243.801 -25.835
201706 -6.942 244.955 -9.358
201709 -51.657 246.819 -69.111
201712 -13.647 246.524 -18.280
201803 -6.074 249.554 -8.037
201806 -8.808 251.989 -11.542
201809 -1.483 252.439 -1.940
201812 -2.449 251.233 -3.219
201903 -0.239 254.202 -0.310
201906 -0.230 256.143 -0.297
201909 -0.672 256.759 -0.864
201912 -0.225 256.974 -0.289
202003 -0.235 258.115 -0.301
202006 -0.835 257.797 -1.070
202009 -0.458 260.280 -0.581
202012 -0.140 260.474 -0.177
202103 -0.319 264.877 -0.398
202106 -0.498 271.696 -0.605
202109 -0.689 274.310 -0.829
202112 -0.504 278.802 -0.597
202203 -0.400 287.504 -0.459
202206 -0.397 296.311 -0.442
202209 -0.485 296.808 -0.540
202212 -0.406 296.797 -0.452
202303 -0.374 301.836 -0.409
202306 -0.295 305.109 -0.319
202309 -0.365 307.789 -0.392
202312 -0.514 306.746 -0.553
202403 -0.313 312.332 -0.331
202406 -0.325 314.175 -0.342
202409 -0.288 315.301 -0.302
202412 -0.315 315.605 -0.330
202503 -0.240 319.799 -0.248
202506 -0.234 322.561 -0.240
202509 -0.179 324.800 -0.182
202512 -0.231 324.054 -0.235
202603 -0.156 330.213 -0.156

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-19.76 mean?
Altimmune (FRA:3G0) has a E10 of €-19.76 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Altimmune and its competitors.
Is Altimmune's E10 too high?
Altimmune's current E10 is €-19.76. Overall, Altimmune has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Altimmune's E10 compare to RGNX and TRAX?
Altimmune's E10 of €-19.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Altimmune and its competitors. Altimmune's current E10 is €-19.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altimmune stock overvalued right now?
Altimmune (FRA:3G0) has a current E10 of €-19.76. The current E10 is €-19.76. Altimmune's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Altimmune (FRA:3G0), the current E10 is €-19.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altimmune Business Description

Address 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
30GF Score

Get the complete analysis for FRA:3G0

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price